1459 related articles for article (PubMed ID: 24111601)
21. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
[TBL] [Abstract][Full Text] [Related]
22. Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.
Abergel E; Nikolsky E
Vasc Health Risk Manag; 2010 Oct; 6():963-77. PubMed ID: 21057581
[TBL] [Abstract][Full Text] [Related]
23. Contemporary use of P2Y
Rakowski T; Siudak Z; Dziewierz A; Plens K; Kleczyński P; Dudek D
J Thromb Thrombolysis; 2018 Jan; 45(1):151-157. PubMed ID: 29075924
[TBL] [Abstract][Full Text] [Related]
24. A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Dasbiswas A; Rao MS; Babu PR; Vijayvergiya R; Nayak R; Dani S; Tyagi S; Hiremath S; Patel T; Alexander T; Prakash VS; Singh DP; Yadav MK; Pathak K; Srivastava A
J Assoc Physicians India; 2013 Feb; 61(2):114-6, 126. PubMed ID: 24471250
[TBL] [Abstract][Full Text] [Related]
25. Assessment of P2Y12 inhibitor usage and switching in acute coronary syndrome patients undergoing percutaneous coronary revascularization.
Kudaravalli M; Althouse AD; Marroquin OC; Khandhar SJ; Sharbaugh MS; Toma C; Conrad Smith AJ; Schindler JT; Lee JS; Mulukutla SR
Int J Cardiol; 2016 Nov; 223():854-859. PubMed ID: 27592042
[TBL] [Abstract][Full Text] [Related]
26. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
[TBL] [Abstract][Full Text] [Related]
27. Randomized Comparison of Oral P2Y
Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
[TBL] [Abstract][Full Text] [Related]
28. Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Yudi MB; Clark DJ; Farouque O; Eccleston D; Andrianopoulos N; Duffy SJ; Brennan A; Lefkovits J; Ramchand J; Yip T; Oqueli E; Reid CM; Ajani AE;
Intern Med J; 2016 May; 46(5):559-65. PubMed ID: 26909472
[TBL] [Abstract][Full Text] [Related]
29. How Long Does It Take for Clopidogrel and Ticagrelor to Inhibit Platelets in Patients Undergoing Primary Percutaneous Coronary Intervention? A Detailed Pharmacodynamic Analysis: Time Course of Platelet Reactivity in STEMI (TOPS).
Bergmeijer TO; Godschalk TC; Janssen PWA; Berge KVD; Breet NJ; Kelder JC; Hackeng CM; Ten Berg JM
Semin Thromb Hemost; 2017 Jun; 43(4):439-446. PubMed ID: 28561235
[TBL] [Abstract][Full Text] [Related]
30. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
[TBL] [Abstract][Full Text] [Related]
31. High and low on-treatment platelet reactivity to P2Y
Ferreiro JL; Vivas D; De La Hera JM; Marcano AL; Lugo LM; Gómez-Polo JC; Silva I; Tello-Montoliu A; Marín F; Roldán I
Thromb Res; 2019 Mar; 175():95-101. PubMed ID: 30738371
[TBL] [Abstract][Full Text] [Related]
32. High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel.
Geisler T; Booth J; Tavlaki E; Karathanos A; Müller K; Droppa M; Gawaz M; Yanez-Lopez M; Davidson SJ; Stables RH; Banya W; Zaman A; Flather M; Dalby M
PLoS One; 2015; 10(8):e0135037. PubMed ID: 26317618
[TBL] [Abstract][Full Text] [Related]
33. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.
Clemmensen P; Grieco N; Ince H; Danchin N; Goedicke J; Ramos Y; Schmitt J; Goldstein P;
Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):220-9. PubMed ID: 25182465
[TBL] [Abstract][Full Text] [Related]
34. Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes: Clopidogrel, Prasugrel, and Ticagrelor.
Roffman DS
J Pharm Pract; 2016 Jun; 29(3):239-49. PubMed ID: 25660584
[TBL] [Abstract][Full Text] [Related]
35. Comparison of P2Y
Gosling R; Yazdani M; Parviz Y; Hall IR; Grech ED; Gunn JP; Storey RF; Iqbal J
Platelets; 2017 Dec; 28(8):767-773. PubMed ID: 28267384
[TBL] [Abstract][Full Text] [Related]
36. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.
Coleman CI; Limone BL
Am J Cardiol; 2013 Aug; 112(3):355-62. PubMed ID: 23631863
[TBL] [Abstract][Full Text] [Related]
38. Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE).
Alexopoulos D; Goudevenos JA; Xanthopoulou I; Deftereos S; Sitafidis G; Kanakakis I; Hamilos M; Parissis H; Ntalas IV; Angelidis C; Petousis S; Vavuranakis M; Hahalis G; Stefanadis C;
Int J Cardiol; 2013 Oct; 168(6):5329-35. PubMed ID: 23978364
[TBL] [Abstract][Full Text] [Related]
39. Platelet reactivity in patients receiving a maintenance dose of P2Y12-ADP receptor antagonists undergoing elective percutaneous coronary intervention.
Bonello L; Laine M; Thuny F; Paganelli F; Lemesle G; Roch A; Kerbaul F; Dignat-George F; Berbis J; Frere C
Int J Cardiol; 2016 Aug; 216():190-3. PubMed ID: 27179310
[TBL] [Abstract][Full Text] [Related]
40. Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study.
Laine M; Frère C; Toesca R; Berbis J; Barnay P; Pansieri M; Michelet P; Bessereau J; Camilleri E; Ronsin O; Helal O; Paganelli F; Dignat-George F; Bonello L
Thromb Haemost; 2014 Feb; 111(2):273-8. PubMed ID: 24154787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
